Navigation Links
Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia
Date:10/28/2008

Harvest Technologies Corp. (www.harvesttech.com) announced today that its new patient-education website, www.CLIclinicalstudy.com, is now “live”. The site is intended to offer persons who are considering enrolling in the Company’s clinical trial and their referring physicians important information related to the study’s design, the science that underlies it, and the location of the study’s sites.

PLYMOUTH, Mass. (Business Wire EON) October 28, 2008 -- The Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to Harvest Technologies to conduct a randomized, controlled, double-blind, multicenter clinical trial using the Company's BMAC System to prepare a composition of bone marrow stem cells to treat patients with Critical Limb Ischemia (CLI). This "feasibility trial" will enroll a total of 48 subjects. Subjects who enroll in this study have exhausted all surgical and procedural options and are at extreme risk for major amputation. The BMAC System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells in approximately 15 minutes at the bedside. The clinical study design provides for injecting these cells into the affected limb to reduce the potential for limb amputation. It also will offer data with respect to the safety of this procedure.

This U.S. clinical study is being led by Principal Investigator Mark D. Iafrati, M.D., Chief of Vascular Surgery at Tufts Medical Center, Boston. In addition, the CLI Study is also enrolling subjects at: Roper St. Francis Healthcare, Charleston, S.C.; Methodist Hospital, Houston; University of South Florida Health, Tampa, Fla.; Maimonides Medical Center, Brooklyn, N.Y.; and Vascular Associates of Albany, Albany, N.Y.

Published studies in this area have used complicated methods to process and concentrate adult stem cells from a patient's bone marrow. The BMAC System is the first to offer clinicians a simple, easy point-of-care method to prepare a concentration of stem and precursor cells from a small aspirate of autologous bone marrow in just 15 minutes.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Read the full story at http://www.prweb.com/releases/harvest_technologies/bmac_system/prweb1539624.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. 2008 Idaho Potato Harvest Forecast: Plentiful, High-Quality Spuds
2. MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems
3. Americas Second Harvest Provides Emergency Food and Water to Tropic Storm Fay Evacuees
4. Fresh Harvest Products, Inc. Announces New Brand Initiative
5. New Technique Harvests Stem Cells at Earlier Stage
6. American Red Cross Honors Americas Second Harvest at Heritage of Service Dinner
7. CalbaTech Announces $999,926 Reduction in Debt; First Adult Stem Cell Harvesting Scheduled
8. Quaker Introduces Simple Harvest(TM) All Natural Multigrain Chewy Granola Bars That Taste Simply Delicious
9. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
10. StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System
11. Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com :  Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 
(Date:2/10/2016)... ... , ... Emergency rooms provide emergency care to stabilize critical health issues, but ... dental emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... Missouri (PRWEB) , ... February 10, 2016 , ... ... in San Diego, will bring together more than 200 of the country’s top ... for the future. , “The true benefit of the Forum is the provider-centric ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
(Date:2/10/2016)... Feb. 10, 2016  Visage Imaging Inc. ("Visage"), ... (ASX: PME), has announced that the American College of ... have selected the Visage 7 Enterprise Imaging Platform ... Emergent/Critical Care Imaging SIMulation (SIM). SIM is the ... Program (WIDI), a multi-faceted and fully-integrated online assessment, ...
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
Breaking Medicine Technology: